Immunopotentiating activity of septilin.
Oral administration of septilin (100mg/animal/dose; five doses) was found to enhance natural killer cell mediated cytotoxicity and antibody-dependent cellular cytotoxicity in normal mice as well as tumour-bearing mice. Septilin treatment also activated the peritoneal macrophages which produced cytotoxicity to L929 cells. Septilin increased proliferation of bone-marrow cells and there was an increase in the number of alpha-naphthyl acetate esterase staining cells in the bone-marrow. In addition to the activation of cellular immunity, septilin was found to increase the number of antibody producing cells in the spleen and activation of antibody-dependent complement-mediated cell lysis. These studies justifies the use of this herbal preparation in improving immunocompetence in disease states.
Praveenkumar
V
V
Amala Cancer Research Centre, Amala Nagar, Thrissur, India.
Kuttan
R
R
Kuttan
G
G
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D000917:Antibody Formation / Q000187:drug effects; D001854:Bone Marrow Cells / Q000187:drug effects / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D051379:Mice; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D010936:Plant Extracts; C047352:septilin